Literature DB >> 7623576

Implications of variations of "conserved" regions of hepatitis C virus genome.

J Y Lau1, P Simmonds, M S Urdea.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7623576     DOI： 10.1016/s0140-6736(95)92786-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

Review 1.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes.

Authors:  E Orito; M Mizokami; T Tanaka; J Y Lau; K Suzuki; M Yamauchi; Y Ohta; A Hasegawa; S Tanaka; M Kohara
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

3.  Clinical relevance of hepatitis C virus genotypes.

Authors:  P Simmonds
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

4.  Duration of HCV infection as a predictor of nonresponse to interferon.

Authors:  A Craxì; V Di Marco; C Cammà; P Almasio; S Magrin
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy.

Authors:  Y Shiratori; N Kato; H Yoshida; R Nakata; M Ihori; F Imazeki; O Yokosuka; T Kawase; T Katamoto; T Unuma; A Nakamura; F Ikegami; K Hirota; M Omata
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

6.  Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays.

Authors:  M Martinot-Peignoux; V Le Breton; S Fritsch; G Le Guludec; N Labouret; F Keller; P Marcellin
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

7.  Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum.

Authors:  Pascale Trimoulet; Philippe Halfon; Eric Pohier; Hacène Khiri; Geneviève Chêne; Hervé Fleury
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

8.  Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method.

Authors:  A Hawkins; F Davidson; P Simmonds
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

9.  Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology.

Authors:  J Detmer; R Lagier; J Flynn; C Zayati; J Kolberg; M Collins; M Urdea; R Sánchez-Pescador
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study.

Authors:  Akihito Tsubota; Ken-ichi Satoh; Mashu Aizawa; Seishi Takamatsu; Yoshihisa Namiki; Toshifumi Ohkusa; Kiyotaka Fujise; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.